385 related articles for article (PubMed ID: 8640326)
21. The angiotensin II receptor antagonist losartan: a new advance in the treatment of hypertension.
Lacourcière Y
Can J Cardiol; 1995 Aug; 11 Suppl F():45F-48F. PubMed ID: 7664218
[TBL] [Abstract][Full Text] [Related]
22. Irbesartan treatment in hypertension.
Brown MJ
Hosp Med; 1998 Oct; 59(10):808-11. PubMed ID: 9850301
[TBL] [Abstract][Full Text] [Related]
23. The future role of losartan.
Hansson L
J Hum Hypertens; 1995 Nov; 9 Suppl 5():S55-8. PubMed ID: 8583483
[TBL] [Abstract][Full Text] [Related]
24. Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension.
Tikkanen I; Omvik P; Jensen HA
J Hypertens; 1995 Nov; 13(11):1343-51. PubMed ID: 8984133
[TBL] [Abstract][Full Text] [Related]
25. Long-term effects of losartan and enalapril, alone or with a diuretic, on ambulatory blood pressure and cardiac performance in hypertension: a case-control study.
Verdecchia P; Schillaci G; Reboldi GP; Sacchi N; Bruni B; Benemio G; Porcellati C
Blood Press Monit; 2000 Jun; 5(3):187-93. PubMed ID: 10915233
[TBL] [Abstract][Full Text] [Related]
26. Angiotensin II receptor inhibition. A new therapeutic principle.
Messerli FH; Weber MA; Brunner HR
Arch Intern Med; 1996 Sep; 156(17):1957-65. PubMed ID: 8823149
[TBL] [Abstract][Full Text] [Related]
27. Effect of angiotensin II blockade on cardiac hypertrophy and remodelling: a review.
Dahlöf B
J Hum Hypertens; 1995 Nov; 9 Suppl 5():S37-44. PubMed ID: 8583480
[TBL] [Abstract][Full Text] [Related]
28. The renin angiotensin system and nociception in spontaneously hypertensive rats.
Irvine RJ; White JM; Head RJ
Life Sci; 1995 Feb; 56(13):1073-8. PubMed ID: 9001440
[TBL] [Abstract][Full Text] [Related]
29. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker.
O'Brien E; Barton J; Nussberger J; Mulcahy D; Jensen C; Dicker P; Stanton A
Hypertension; 2007 Feb; 49(2):276-84. PubMed ID: 17159081
[TBL] [Abstract][Full Text] [Related]
30. Losartan: the first angiotensin receptor antagonist in clinical use.
Beevers DG
J Hum Hypertens; 1995 Nov; 9 Suppl 5():S1. PubMed ID: 8583475
[No Abstract] [Full Text] [Related]
31. Effects and tolerability of irbesartan versus enalapril in patients with severe hypertension. Irbesartan Multicenter Investigators.
Larochelle P; Flack JM; Marbury TC; Sareli P; Krieger EM; Reeves RA
Am J Cardiol; 1997 Dec; 80(12):1613-5. PubMed ID: 9416950
[TBL] [Abstract][Full Text] [Related]
32. Renal response to the angiotensin II receptor subtype 1 antagonist irbesartan versus enalapril in hypertensive patients.
Pechère-Bertschi A; Nussberger J; Decosterd L; Armagnac C; Sissmann J; Bouroudian M; Brunner HR; Burnier M
J Hypertens; 1998 Mar; 16(3):385-93. PubMed ID: 9557932
[TBL] [Abstract][Full Text] [Related]
33. Direct selective blockade of the vascular angiotensin II receptors in therapy for hypertension and severe congestive heart failure.
Awan NA; Mason DT
Am Heart J; 1996 Jan; 131(1):177-85. PubMed ID: 8554006
[TBL] [Abstract][Full Text] [Related]
34. A multicenter, randomized, double-blind study of the antihypertensive efficacy and tolerability of irbesartan in patients aged > or = 65 years with mild to moderate hypertension.
Lacourcière Y
Clin Ther; 2000 Oct; 22(10):1213-24. PubMed ID: 11110232
[TBL] [Abstract][Full Text] [Related]
35. Effects of U-97018 on pressor responses to intracerebroventricularly administered angiotensin II in conscious normotensive rats.
Morita O; Kushida H; Kunihara M
J Cardiovasc Pharmacol; 1995 Jun; 25(6):880-7. PubMed ID: 7564332
[TBL] [Abstract][Full Text] [Related]
36. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension.
Goldberg AI; Dunlay MC; Sweet CS
Am J Cardiol; 1995 Apr; 75(12):793-5. PubMed ID: 7717281
[TBL] [Abstract][Full Text] [Related]
37. Renal responses to angiotensin receptor antagonist and angiotensin-converting enzyme inhibitor in partially nephrectomized spontaneously hypertensive rats.
Okada H; Suzuki H; Kanno Y; Ikenaga H; Saruta T
J Cardiovasc Pharmacol; 1995 Oct; 26(4):564-9. PubMed ID: 8569216
[TBL] [Abstract][Full Text] [Related]
38. Preliminary experience with the angiotensin II receptor antagonist irbesartan in chronic kidney disease.
von Vigier RO; Zberg PM; Teuffel O; Bianchetti MG
Eur J Pediatr; 2000 Aug; 159(8):590-3. PubMed ID: 10968237
[TBL] [Abstract][Full Text] [Related]
39. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension.
Israili ZH
J Hum Hypertens; 2000 Apr; 14 Suppl 1():S73-86. PubMed ID: 10854085
[TBL] [Abstract][Full Text] [Related]
40. Angiotensin II antagonism: a new avenue of hypertension management.
Gavras H
Blood Press Suppl; 1997; 1():42-6. PubMed ID: 9285108
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
